Literature DB >> 25583260

The Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent manner.

Fiona P Bailey1, Dominic P Byrne1, Krishnadev Oruganty2, Claire E Eyers1, Christopher J Novotny3, Kevan M Shokat3, Natarajan Kannan2, Patrick A Eyers1.   

Abstract

The human Tribbles (TRB)-related pseudokinases are CAMK (calcium/calmodulin-dependent protein kinase)-related family members that have evolved a series of highly unusual motifs in the 'pseudocatalytic' domain. In canonical kinases, conserved amino acids bind to divalent metal ions and align ATP prior to efficient phosphoryl-transfer to substrates. However, in pseudokinases, atypical residues give rise to diverse and often unstudied biochemical and structural features that are thought to be central to cellular functions. TRB proteins play a crucial role in multiple signalling networks and overexpression confers cancer phenotypes on human cells, marking TRB pseudokinases out as a novel class of drug target. In the present paper, we report that the human pseudokinase TRB2 retains the ability to both bind and hydrolyse ATP weakly in vitro. Kinase activity is metal-independent and involves a catalytic lysine residue, which is conserved in TRB proteins throughout evolution alongside several unique amino acids in the active site. A similar low level of autophosphorylation is also preserved in the closely related human TRB3. By employing chemical genetics, we establish that the nucleotide-binding site of an 'analogue-sensitive' (AS) TRB2 mutant can be targeted with specific bulky ligands of the pyrazolo-pyrimidine (PP) chemotype. Our analysis confirms that TRB2 retains low levels of ATP binding and/or catalysis that is targetable with small molecules. Given the significant clinical successes associated with targeting of cancer-associated kinases with small molecule inhibitors, it is likely that similar approaches will be useful for further evaluating the TRB pseudokinases, with the translation of this information likely to furnish new leads for drug discovery.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25583260      PMCID: PMC4844368          DOI: 10.1042/BJ20141441

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  106 in total

1.  Rethinking pseudokinases.

Authors:  Natarajan Kannan; Susan S Taylor
Journal:  Cell       Date:  2008-04-18       Impact factor: 41.582

2.  Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein.

Authors:  S L Sierke; K Cheng; H H Kim; J G Koland
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

3.  Trib1 links the MEK1/ERK pathway in myeloid leukemogenesis.

Authors:  Takashi Yokoyama; Yohei Kanno; Yukari Yamazaki; Tomoko Takahara; Satoshi Miyata; Takuro Nakamura
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

4.  Chloride sensing by WNK1 involves inhibition of autophosphorylation.

Authors:  Alexander T Piala; Thomas M Moon; Radha Akella; Haixia He; Melanie H Cobb; Elizabeth J Goldsmith
Journal:  Sci Signal       Date:  2014-05-06       Impact factor: 8.192

5.  Nucleotide binding by the epidermal growth factor receptor protein-tyrosine kinase. Trinitrophenyl-ATP as a spectroscopic probe.

Authors:  K Cheng; J G Koland
Journal:  J Biol Chem       Date:  1996-01-05       Impact factor: 5.157

6.  Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology.

Authors:  Chao Zhang; Michael S Lopez; Arvin C Dar; Eva Ladow; Steven Finkbeiner; Cai-Hong Yun; Michael J Eck; Kevan M Shokat
Journal:  ACS Chem Biol       Date:  2013-07-23       Impact factor: 5.100

Review 7.  Pseudokinases-remnants of evolution or key allosteric regulators?

Authors:  Elton Zeqiraj; Daan M F van Aalten
Journal:  Curr Opin Struct Biol       Date:  2010-11-10       Impact factor: 6.809

8.  Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response.

Authors:  Marloes Wennemers; Johan Bussink; Blanca Scheijen; Iris D Nagtegaal; Hanneke W M van Laarhoven; James A Raleigh; Mahesh A Varia; Joop J T M Heuvel; Kasper M Rouschop; Fred C G J Sweep; Paul N Span
Journal:  Breast Cancer Res       Date:  2011-08-24       Impact factor: 6.466

9.  Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks.

Authors:  Paul J Scutt; Matthew L H Chu; Dominic A Sloane; Mike Cherry; Colin R Bignell; David H Williams; Patrick A Eyers
Journal:  J Biol Chem       Date:  2009-04-09       Impact factor: 5.157

10.  Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.

Authors:  Elton Zeqiraj; Beatrice Maria Filippi; Maria Deak; Dario R Alessi; Daan M F van Aalten
Journal:  Science       Date:  2009-11-05       Impact factor: 47.728

View more
  26 in total

Review 1.  PseudoGTPase domains in p190RhoGAP proteins: a mini-review.

Authors:  Amy L Stiegler; Titus J Boggon
Journal:  Biochem Soc Trans       Date:  2018-12-04       Impact factor: 5.407

2.  SimpleDSFviewer: A tool to analyze and view differential scanning fluorimetry data for characterizing protein thermal stability and interactions.

Authors:  Changye Sun; Yong Li; Edwin A Yates; David G Fernig
Journal:  Protein Sci       Date:  2019-08-19       Impact factor: 6.725

3.  High-Resolution Structure and Inhibition of the Schizophrenia-Linked Pseudokinase ULK4.

Authors:  Susmita Khamrui; Peter M U Ung; Cody Secor; Avner Schlessinger; Michael B Lazarus
Journal:  J Am Chem Soc       Date:  2019-12-17       Impact factor: 15.419

4.  Type II Binders Targeting the "GLR-Out" Conformation of the Pseudokinase STRADα.

Authors:  Ryan H B Smith; Zaigham M Khan; Peter Man-Un Ung; Alex P Scopton; Lisa Silber; Seshat M Mack; Alexander M Real; Avner Schlessinger; Arvin C Dar
Journal:  Biochemistry       Date:  2021-01-13       Impact factor: 3.162

5.  Tracing the origin and evolution of pseudokinases across the tree of life.

Authors:  Annie Kwon; Steven Scott; Rahil Taujale; Wayland Yeung; Krys J Kochut; Patrick A Eyers; Natarajan Kannan
Journal:  Sci Signal       Date:  2019-04-23       Impact factor: 8.192

Review 6.  Looking lively: emerging principles of pseudokinase signaling.

Authors:  Joshua B Sheetz; Mark A Lemmon
Journal:  Trends Biochem Sci       Date:  2022-05-16       Impact factor: 14.264

7.  Oncogenic TRIB2 interacts with and regulates PKM2 to promote aerobic glycolysis and lung cancer cell procession.

Authors:  Yuan-Rong Liu; Dan-Dan Song; Dong-Min Liang; You-Jie Li; Yun-Fei Yan; Hong-Fang Sun; Mei-Ling Zhang; Jin-Xia Hu; Yu-Long Zhao; Yan Liang; Yan-Mei Li; Zhen Yang; Ran-Ran Wang; Hou-Feng Zheng; Pingyu Wang; Shu-Yang Xie
Journal:  Cell Death Discov       Date:  2022-07-05

8.  Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells.

Authors:  Daniel M Foulkes; Dominic P Byrne; Wayland Yeung; Safal Shrestha; Fiona P Bailey; Samantha Ferries; Claire E Eyers; Karen Keeshan; Carrow Wells; David H Drewry; William J Zuercher; Natarajan Kannan; Patrick A Eyers
Journal:  Sci Signal       Date:  2018-09-25       Impact factor: 8.192

9.  Substrate binding allosterically relieves autoinhibition of the pseudokinase TRIB1.

Authors:  Sam A Jamieson; Zheng Ruan; Abigail E Burgess; Jack R Curry; Hamish D McMillan; Jodi L Brewster; Anita K Dunbier; Alison D Axtman; Natarajan Kannan; Peter D Mace
Journal:  Sci Signal       Date:  2018-09-25       Impact factor: 8.192

Review 10.  The Critical Role of TRIB2 in Cancer and Therapy Resistance.

Authors:  Victor Mayoral-Varo; Lucía Jiménez; Wolfgang Link
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.